Champions Oncology Reports 11.5% Revenue Growth but Net Loss for Quarter Ending October 31, 2025

Champions Oncology, Inc. reported its financial results for the quarter ending October 31, 2025, revealing a total oncology revenue of $15.0 million, an increase of 11.5% from $13.5 million in the same quarter of the previous year. For the six-month period, revenue rose to $29.0 million, up 5.4% from $27.6 million. The growth in revenue was primarily attributed to improved conversion rates of bookings to revenue, as fewer study cancellations allowed for a larger portion of contracted work to be recognized as revenue. However, the company reported a net loss of $237,000 for the quarter, a significant decline from a net income of $728,000 in the prior year, and a loss of $230,000 for the six months compared to a profit of $2.0 million in the same period last year.

The company's total operating expenses for the quarter increased to $14.9 million, up 16.4% from $12.8 million in the prior year. This rise was driven by higher research and development costs, which surged by 54.9% to $2.6 million, and general and administrative expenses, which rose by 57.4% to $3.0 million. The increase in R&D expenses reflects the company's ongoing investment in its data licensing platform and its subsidiary, Corellia, focused on target discovery. The cost of oncology revenue decreased slightly by 2.2% to $7.3 million, primarily due to lower outsourced lab service costs.

Champions Oncology's balance sheet as of October 31, 2025, showed total assets of $30.2 million, down from $32.3 million at the end of April 2025. Current liabilities decreased to $22.1 million from $23.9 million, while stockholders' equity increased to $4.2 million from $3.8 million, reflecting a net income attributable to common shares of $268,000 for the quarter. The company had cash and cash equivalents of $8.5 million, down from $9.8 million at the end of the previous fiscal period, and reported negative working capital of $809,000.

In terms of operational developments, Champions Oncology continues to focus on its TumorGraft Technology Platform, which provides personalized cancer care through the use of patient-derived xenografts. The company has also expanded its offerings with the Lumin Bioinformatics software, which serves as a data-driven tool for oncology research. Despite the challenges faced in the current fiscal period, management believes that the existing cash reserves, along with anticipated cash flows from operations, will be sufficient to fund operations through at least December 2026. However, the company acknowledges the potential need for additional capital in the future, which may not be guaranteed under favorable terms.

Looking ahead, Champions Oncology aims to enhance its market position by leveraging its technology platforms and expanding its service offerings. The company is actively evaluating strategic options to create additional value from its drug discovery business, which may include potential spin-out transactions or capital raises. The management remains optimistic about the long-term prospects of its oncology services and technology solutions, despite the current financial challenges.